SCHEMBL4876387

SCHEMBL4876387

COCCOc1ccccc1N1CCC(C(=O)OS(N)(=O)=O)(c2cccc(OC)c2)CC1

nearest known ligand 0.53

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
SOAT1 P35610 9/20 0.47
DRD4 P21917 3/20 0.41
DRD2 P14416 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4876644 0.90 SOAT1 (0.51) SOAT1DRD4DRD2
SCHEMBL4873692 0.89 SOAT1 (0.51) SOAT1DRD4DRD2
SCHEMBL4881113 0.89 SOAT1 (0.50) SOAT1DRD4DRD2
Hydrochloric Acid SCHEMBL4880951 0.89 SOAT1 (0.51) SOAT1DRD4DRD2
SCHEMBL4876812 0.87 SOAT1 (0.49) SOAT1DRD4DRD2
SCHEMBL4876378 0.85 SOAT1 (0.47) SOAT1DRD4DRD2
SCHEMBL4880541 0.81 SOAT1 (0.48) SOAT1DRD4
SCHEMBL4881137 0.80 CA12 (0.49) SOAT1DRD2
SCHEMBL4876701 0.79 ALDH1A1 (0.50) DRD4DRD2
SCHEMBL4880646 0.79 SCN10A (0.40) SOAT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080096922-A1 Novel Sulfonamide derivative DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2008-04-24 US disclosed
EP-1736467-A1 NOVEL SULFONAMIDE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2006-12-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080096922-A1 Novel Sulfonamide derivative NR4A1, NR4A2, NR4A3 SOAT1 502/4885DRD4 191/4885DRD2 715/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.